Videos
In 1995, the IMF established the Brian D. Novis Research Grant program in memory of its co-founder. The grants are awarded annually to promote research in all areas of myeloma in an effort to improve patient outcomes. To date, the IMF has funded more than 100 of the most promising…
Page
We invite you to attend the symposium New Strategies for Multiple Myeloma Care: Case Studies for Nurses. We share patient case studies, the latest drug approvals, and clinical trial updates.
This FREE Symposium was recently launched at the Oncology Nursing Society’s Bridge Virtual…
Event
On September 2, 2020, my Dad was diagnosed with multiple myeloma. I had never heard of this before and not only was this news devastating to our family, but we were even more devastated to learn there is no cure. So my family and I have made it our mission to help find a cure for…
Event
The tiny bea began in Seattle in 2012 when I decided it was time to share some of my father's legacy with the world. I started with bolo ties and expanded from there. Many of the agates, jaspers and opals are collector's specimens, so some pieces are priced to reflect that. I am…
Page
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. Explore this page to learn about the latest blood cancer research from the…
Videos
click on the image above to view the video
How to Prepare for Virtual Telemedicine Appointments
Practical Tips on Staying Connected With Your Healthcare Team Virtually
This year, many patients have the option to use telehealth or telemedicine services as a way…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. This episode features an interview with seven-year myeloma survivor Tiffany Williams, who is a nurse practitioner, a mother, a…
Videos
2020 Marks the International Myeloma Foundation's (IMF) 30th Anniversary
The IMF celebrates 30 years of scientific achievement with multiple myeloma patient care at the heart of it all.
From what started in a garage with a borrowed typewriter, a lawn chair, and lots of hope, The IMF is now…
Event
Join this all virtual meeting to get the latest updates from myeloma experts.
This RCW will highlight key topics of greatest current interest in the myeloma field. We are also including Question and Answer time with the panel of experts. We are excited to bring this important unique…
News Article
This year, the International Myeloma Foundation (IMF) has received the highest 4-star rating for the 16th time from Charity Navigator, the largest independent charity evaluator in the U.S. This year’s 4-star rating marks a fourth-consecutive year of this highest scoring for the IMF.
Michael…
Event
This RCW will highlight key topics of greatest current interest in the myeloma field. We are also including Question and Answer time with the panel of experts. We are excited to bring this important unique event to multiple myeloma patients and caregivers throughout the Southwestern USA region.
Do myeloma patients who are responding well to their treatment need to track potential bone disease?
Videos
In this episode, Dr. Brian G.M. Durie discusses the importance of routine bone testing for patients with multiple myeloma. The BOTTOM LINE:Myeloma patients should continue to monitor their bone health. Talk to your doctor about scheduling routine follow-up tests to detect…
Page
Seeking inspiration and news all in one place? The IMF blog contributors range from IMF Executive staff to newly diagnosed patients, long-term myeloma survivors, and caregivers. From the IMF Executive Staff and Editorial Team, check out the "Week in Review" blogs.
News Article
The landmark IMWG paper, published in Blood Cancer Journal, identifies patients with high-risk smoldering multiple myeloma who are candidates for early therapy and clinical trials.
LOS ANGELES, CA., October 27, 2020—The International Myeloma Working Group, a body of the…
News Article
INTERNATIONAL MYELOMA FOUNDATION 14TH ANNUAL COMEDY CELEBRATION GOES VIRTUAL IN 2020, FEATURING “EVERYBODY LOVES RAYMOND” CAST REUNION
HOSTED BY RAY ROMANO ON OCTOBER 23 AT 9 PM EST
Cast will recreate memorable scenes from classic sitcom and share stories of beloved co-stars, Peter…
Event
Join us on Friday, October 23, 2020, at 6 p.m. PT / 9 p.m. ET for an exclusive Virtual Table Read Reviving the Classic Sitcom “Everybody Loves Raymond.” Actor and comedian Ray Romano returns to host and will be joined by his former fellow cast members Patricia Heaton, Brad Garrett, Monica Horan,…
Event
Join this all virtual meeting to get the latest updates from myeloma experts.
This RCW will highlight key topics of greatest current interest in the myeloma field. We are also including Question and Answer time with the panel of experts.
Page
Susie Durie founded the IMF in 1990 with her late husband, Brian Novis, and Brian G.M. Durie. M.D., to advance myeloma research and to develop and implement patient and physician educational programs in myeloma. In 1992, she was elected Executive Director of the IMF and today holds the title of…
Author
Susie Novis Durie founded the IMF in 1990 with her late husband, Brian Novis, and Brian G.M. Durie. M.D., as a means to advance myeloma research and to develop and implement patient and physician educational programs in myeloma.
In 1992, Novis Durie was elected Executive Director of the IMF.…
IMF Person
Roswell Park Comprehensive Cancer Center
New York, NY
USA
*German certified
Page
Join this all virtual meeting to get the latest updates from myeloma experts.
This RCW will highlight key topics of greatest current interest in the myeloma field. We are also including Question and Answer time with the panel of experts. We are excited to bring this important unique…
News Article
August 26, 2020
The International Myeloma Foundation (IMF), the first and largest foundation focusing specifically on multiple myeloma, is pleased to announce the recipients of the 2020 International Myeloma Working…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. This episode features an interview with seven-year multiple myeloma survivor Tim Gavallas. Tim is a police officer in Watertown…
Event
Time: 8 a.m. – 9 a.m. (PST) / 18:00 - 19:00 (MSK)
Topic: Global Approaches in Multiple Myeloma
This program will be moderated by Professor Mustafa Çetiner, MD.
The panel includes the following presenters and topics:
Maxim Solovyev, PhD, Head of…
News Article
August 20, 2020
Today, the U.S. Food and Drug Administration (FDA) “approved the expansion of Kyprolis® (carfilzomib) U.S. prescribing information to include its use in combination with Darzalex® (daratumumab) plus dexamethasone (DKd) in two dosing regimens — once weekly and…
Page
In the last few weeks, President Trump has signed several executive orders that may have an impact on myeloma patients if the orders survive legal scrutiny.
For some context in understating these orders, it is important to know that executive orders are mandates or directives for executive…
Event
You can help fund $1,000,000.00 in donations for Brian Novis Research Grant Awards given by the International Myeloma Foundation. The beauty of this is that this can be accomplished without you or anyone you have help you with this, taking even one cent out of your pockets or participating in…
News Article
After the recent FDA Oncologic Drugs Advisory Committee (ODAC) Hearing’s 12-0 vote recommending approval of belantamab mafodotin, it was expected that the FDA would quickly follow suit and proceed with accelerated approval which happened today (See press…
News Article
The IMF Advocacy team often talks about the Congressionally Directed Medical Research Programs (CDMRP), asking for patients to serve as consumer reviewers with the CDMRP’s Peer Reviewed Cancer Research Program (PRCRP) and updating readers on the appropriations progress of CDMRP/PRCRP,…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation (IMF) features messages of hope and resilience for myeloma patients, caregivers, and their loved ones.
We recorded the following interview with Chrissy Degennaro in July 2020.
In Memoriam: The IMF was…
Page
As a global organization, the IMF’s focus has never been singular. While patient-focus is at the center of all we do, recognizing and supporting leading myeloma researchers upholds our mission of Accelerating the prevention and cure of myeloma and improving the quality of life for patients…
Page
The treatment and management of multiple myeloma requires the dedication of multiple myeloma doctors, nurses, and other healthcare professionals.
The IMF works to support supplemental educational efforts for these multiple myeloma experts by providing access to the latest myeloma research…
Page
According to the National Institutes of Health, CME or Continuing Medical Education, consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the…
Page
Multiple myeloma testing, staging, and prognosis can be a complex process involving various procedures. Learn more about the various kinds of tests, staging, and how health professionals determine a prognosis. Testing Health professionals use a range of tests throughout the course…
News Article
An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favor of approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.…
Page
What Is Xpovio (Selinexor)?XPOVIO® (selinexor) is the first and only medication in the drug class known as selective inhibitor of nuclear export (SINE) that has been approved to treat myeloma by the FDA. Xpovio works by preventing myeloma cells from expelling tumor suppressor proteins that help…
Page
What Is Sarclisa?SARCLISA® is a monoclonal antibody that binds to the CD38 (cluster of differentiation 38) receptor on the surface of myeloma cells. The CD systemis designed to classify more than 200 proteins that can be expressed on (stick out of) the surface of a cell. CD38 is widely…
News Article
On June 17, 2020, the House Energy and Commerce Committee’s Subcommittee on Health held a hearing entitled "Health Care Inequality: Confronting Racial and Ethnic Disparities in COVID-19 and the Health Care System." The International Myeloma Foundation sent a letter of support to the committee for…
Videos
IMF Chief Medical Officer Dr. Joseph Mikhael on the IKEMA Study
What is the IKEMA Trial?
The IKEMA trial is a phase III study in which patients with relapsed refractory multiple myeloma who have undergone 1-3 prior lines of therapy that were randomized 3:2. These…
Page
The death of George Floyd at the hands of the police has enraged the world. The IMF stands together with the Black community in calling for justice and racial equality. We believe unconditionally, that Black lives matter.
Because of the systemic racism that still runs rampant in our communities…
Event
Learn more about current trends in myeloma treatment and research with this update from two major medical meetings held virtually in May and June 2020.
Dr. Brian G.M. Durie will explain what’s new and exciting from:
American Society of Clinical Oncology (ASCO) Virtual Scientific…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. This episode features an interview with Jen Curran, which was recorded on February 21, 2020. Jen was the opening speaker at…
Videos
Dr. Noemi Puig on the GEM-CESAR Trial
What is the GEM-CESAR trial?
The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients (pts) in which the primary endpoint is the achievement of sustained minimal residual disease (MRD…
Videos
Dr. Meera Mohan on MRD Evolution in Patients Who Have Reached an Optimal Endpoint
What was the goal of this study?
The attainment of minimal residual disease (MRD) negativity in multiple myeloma (MM) patients is increasingly considered an optimal therapeutic endpoint, but…